secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2024-07-16T23:59:59+00:00
Accession:  0001140361-24-033240
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AngioDynamics pro forma Q3 FY2024 net loss $187.8M on $159.5M goodwill impairment
--------------------------------------------------------------------------------

- Pro forma net loss for Feb 29, 2024 quarter was $187.8M vs $13.7M a year ago; includes $159.5M goodwill impairment.
- Pro forma adjusted net loss improved to $6.5M ($0.16 loss per share) from $5.4M ($0.14 loss) in Feb 2023.
- Pro forma net sales for continuing ops were $66.0M, down 6.9% as reported but up 8.0% constant currency vs prior year.
- Med Tech segment pro forma sales grew 13.0% to $25.7M; Med Device segment pro forma sales down 14.7% as reported.
- Pro forma adjusted EBITDA loss narrowed to $3.6M from $1.5M in the year-ago quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000114036124033240/0001140361-24-033240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000114036124033240/ef20032494_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-033240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer